Single-Dose Study of a New Formulation of BIIB061

Summary

The primary objective of the study is to assess the pharmacokinetic (PK) profile of BIIB061 in the new oral formulation in the fasted state in healthy male and female volunteers. The secondary objective of this study is to evaluate the safety and tolerability of BIIB061 in the new formulation in this study population.

Timeline

Start

2015-07

Primary completion

2015-08

Completion

2015-08

Drugs

Indications